An investigational injectable treatment, who it is open to, and the geography that decides whether you can take part.
These studies are recruiting through partner research networks. We may be paid a referral fee if you complete their screening form — this never changes what you pay (nothing) or the compensation the study offers you.
Enrolling adults aged 18 to 80 with a physician diagnosis of liver cirrhosis caused by MASH (metabolic dysfunction-associated steatohepatitis). Not open to people with treated ascites, variceal bleeding, hepatitis B or C, or alcohol-related liver disease.
Screening is free and takes a few minutes. Eligibility and any compensation are confirmed by the study team, not by this site.
MASH — metabolic dysfunction-associated steatohepatitis, the condition formerly called NASH — is liver inflammation and scarring driven by metabolic factors rather than alcohol. When scarring progresses far enough it becomes cirrhosis, and that stage is where current research is most active.
A study is currently enrolling US adults with a physician diagnosis of liver cirrhosis caused by MASH, testing an investigational injectable medication. This page covers who it is open to, the exclusions that rule most applicants out, and a constraint specific to this study that no amount of eligibility can override: geography.
The enrolling study is looking for adults aged 18 to 80 with a physician diagnosis of cirrhosis caused by MASH. A physician diagnosis is the hard requirement here — suspecting fatty liver, or having been told your liver enzymes are elevated, is not the same thing and will not pass screening.
The exclusions are extensive, and worth reading before you spend time on a form:
That last exclusion is not a formality. The two conditions are researched separately precisely because their causes differ, and protocols enforce the boundary strictly.
Most of the studies listed on this site are spread across the country. This one is not. It runs from a small number of investigator sites, and participation requires travelling to one of them for visits — which makes geography the single biggest filter, ahead of any medical criterion.
The metros listed further down are the ones within reach of an active site. If you are outside them, no amount of clinical eligibility changes the answer for this particular study, and it is better to know that now than after three screening steps.
That said, MASH research overall is expanding quickly. Our per-city pages list every study recruiting within 30 miles of you from the NIH registry, and liver studies appear across far more metros than this single protocol covers.
The study tests an investigational injectable medication — meaning it is not approved for general use and is being evaluated for safety and effectiveness. That is the nature of research: the treatment may help, may do nothing, and may have side effects not yet fully characterised. Anyone joining should understand that before signing.
Practically, expect a screening visit with labs and liver assessment, then a schedule of visits over the study period. The full protocol, visit count, procedures and compensation are laid out in the informed consent document you receive before enrolling. You can withdraw at any point without penalty — that right is non-negotiable in any IRB-supervised study.
Compensation for time and travel follows the usual pattern: US studies generally pay $75 to $4,500 per completed study depending on visit count and procedures, with the exact figure set by the protocol and disclosed in writing beforehand.
Join the free email alert — we watch the NIH registry weekly so you don't have to.
Get trial alertsThe terminology was formally revised in 2023, and both old and new names are still in circulation, including in study listings:
If your diagnosis letter says NASH, it means MASH. Searching either term is worthwhile when looking through registry listings, because sites have updated their records at different speeds.
None medically — the name changed. MASH (metabolic dysfunction-associated steatohepatitis) replaced NASH (non-alcoholic steatohepatitis) in the 2023 terminology revision. A diagnosis letter saying NASH describes the same condition, and both terms still appear in study listings.
Not this study. MASH protocols specifically exclude alcohol-related liver disease, because the two conditions have different causes and are researched separately. Studies for alcohol-related liver damage are enrolling separately and are open across most of the country.
For this study, treated ascites (fluid accumulation in the abdomen) and variceal bleeding are the named exclusions. Both indicate decompensated cirrhosis, which falls outside the population being studied. Your hepatologist can tell you which category your case falls into.
Yes. This study runs from a limited number of investigator sites, and visits happen in person. If you are not within reasonable travelling distance of one, this particular study is not available to you regardless of whether you meet the medical criteria.
This study runs from a limited number of sites; these are the metros within reach
Get an email when a new clinical trial starts recruiting within 30 miles of your ZIP code. No spam — only real studies from the NIH registry.